Impact of pimavanserin on prescribing practices in parkinson disease
The availability of pimavanserin was followed by a decline in the use of the most harmful AAPs in persons living with PD. Quetiapine remained the most prescribed AAP. Comparative safety and effectiveness studies are needed to define the relative risks and benefits of treatment options in PDP.
Authors
- Vy Le
- Thanh Phuong Pham Nguyen
- Daniel A. Weintraub (ORCID: https://orcid.org/0000-0003-0633-7168)
- Allison Wright Willis (ORCID: https://orcid.org/0000-0001-5724-7192)
Institutions
- Haverford College (US)
- Translational Therapeutics (United States) (US)
- Philadelphia VA Medical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Clinical Parkinsonism & Related Disorders
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.prdoa.2025.100317
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78